| 研究成果： |
主持、参与或执行的科研项目： 1. 长春百克生物科技股份公司、2023220103000107、肿瘤治疗性RNA疫苗的研发、2023.12.-2025.06、120万元、主持、在研 2.吉林省科技厅、20230101167JC、靶向DCs的多靶点RNA复制子肿瘤疫苗研究、2023.01-2025.12、10万元、主持、在研 3.吉林省教育厅、JJKH20231142KJ、肿瘤mRNA疫苗与人参皂苷的协调抗肿瘤机制研究、2023.01-2024、2.5万元、主持、在研 4.“十三五”国家科技重大专项，2018ZX09301050-003、创新肿瘤治疗性疫苗的研发、2018.06-2020.12、183.85 万元、主持； 5. 吉林省科技厅，20160519018JH、吉林省新型肿瘤疫苗研究创新团队、2016.01-2018.12，20万元、参与、在研； 6. “十二五”国家科技重大专项，2014ZX09304314-001、以survivin和MUC1为靶点重组腺病毒载体肿瘤治疗性疫苗的临床前研究、164.47万、执行、已结题； 7. 国家自然基金青年项目，31300765、以 MUC1 VNTR、survivin和FAP-α为靶点的自组装纳米载体基因疫苗抗肿瘤作用机制研究、2014/01-2016/12、23万元、主持、已结题； 8. 长春百克生物科技股份公司、肿瘤治疗性疫苗的研究、2012-2019、120万元、主持、在研， 9. 吉林省科技发展计划，20130522006JH、双基因自组装纳米载体肿瘤疫苗研究、2013.01-2015.12、3万元、主持、已结题； 10. 教育部新教师基金，20120061120025、针对肿瘤微环境及肿瘤细胞的三基因肿瘤疫苗作用机制研究、2013.01-201 5.12、4万元、主持、已结题； 11. 吉林省产业技术研究与开发专项项目，2013C014-3、肺癌早期基因诊断技术的研究与开发、2013/01 - 2014/12、10万元、参与、已结题； 12. 新葡的京集团8814基本科研业务费，450060323260、以 survivin和MUC1 VNTRs 为靶点的肿瘤基因疫苗免疫佐剂的效果研究、2011/01-2012/12、2万元、主持、已结题； 13. 新葡的京集团8814交叉学科项目，200903255、以 survivin和MUC1 VNTRs 为靶点的肿瘤基因疫苗异源prime - boost免疫策略的研究、2009/12-2011/01、5万元、主持、已结题。 代表性文章
1. Ke Zhang, QimugeWuri, Zongyu Cai, Xueli Qu, Shiqi Zhang, Hui Wu, Jiaxin Wu, Chu Wang, Xianghui Yu, Wei Kong, and Haihong Zhang*, The XCL1-Mediated DNA Vaccine Targeting Type 1 Conventional Dendritic Cells Combined with Gemcitabine and Anti-PD1 Antibody Induces Potent Antitumor Immunity in a Mouse Lung Cancer Model, Int J Mol Sci., 2024 Feb 4;25(3):1880. doi: 10.3390/ijms25031880. 2. Qianqian Guo, Lizheng Wang, Wuriqimuge, Ling Dong, Mengfan Feng, Xin Bao, Ke Zhang, Zongyu Cai, Xueli Qu, Shiqi Zhang, Jiaxin Wu, Hui Wu, Chu Wang, Xianghui Yu, Wei Kong, Haihong Zhang*. Metformin improved a heterologous prime-boost of dual-targeting cancer vaccines to inhibit tumor growth in a melanoma mouse model. Int Immunopharmacol. 2024 Feb 15:128:111431. 3. Fang-Fang Zhang, Yu Xie, Qianqian Guo, Ping Xu, Chenlu Liu, Fei Geng, Zhenzhen Lu, Hui Wu, Bin Yu, Jia-Xin Wu, Wei Kong, Xiang-Hui Yu, Hai-Hong Zhang*. Epitope-based minigene vaccine targeting fibroblast activation protein α can induce specific immune responses and anti-tumor effects in the 4T1 murine breast cancer model, International Immunopharmacology, 2022 Nov;112:109237. doi: 10.1016/j. intimp. 2022. 109237. 4. Fei Geng, Ling Dong, Xin Bao, Qianqian Guo, Jie Guo, Yi Zhou, Bin Yu, Hui Wu, Jiaxin Wu, Haihong Zhang*, Xianghui Yu*, and Wei Kong, CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer. Molecular Therapy-Oncolytics, 2022 Jul 31;26:304-313. 5. Fei Geng, Ling Dong, Xin Bao, Qianqian Guo, Jie Guo, Yi Zhou, Bin Yu, Hui Wu, Jiaxin Wu, Haihong Zhang*, Xianghui Yu*, and Wei Kong, CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer. Molecular Therapy-Oncolytics, accepted.
6. Dong L, Feng M, Qiao Y, Liu C, Zhou Y, Xing S, Zhang K, Cai Z, Wu H, Wu J, Yu X, Zhang H*, Kong W*. Preclinical Safety and Biodistribution in Mice Following Single-Dose Intramuscular Inoculation of Tumor DNA Vaccine by Electroporation. Hum Gene Ther. 2022 Jul; 33 (13-14):757-764. 7. Liu C, Cong X, Wang Y, Guo Q, Xie Y, Geng F, Guo J, Dong L, Zhou Y, Wu H, Yu B, Wu J, Zhang H*, Yu X*, Kong W. Fast DNA Vaccination Strategy Elicits a Stronger Immune Response Dependent on CD8+CD11c+ Cell Accumulation. Front Oncol. 2021 Dec 7; 11 : 752444. 8. Qianqian Guo, Lizheng Wang, Ping Xu, Fei Geng, Jie Guo, Ling Dong, Xin Bao, Yi Zhou, Mengfan Feng, Jiaxin Wu, Hui Wu, Bin Yu, Haihong Zhang*, Xianghui Yu, Wei Kong*. Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse. Oncoimmunology. 2020 Nov 9; 9 (1) : 1841392. 9. Fei Geng, Xin Bao, Ling Dong, Qian-Qian Guo, Jie Guo, Yu Xie, Yi Zhou, Bin Yu, Hui Wu, Jia-Xin Wu, Hai-Hong Zhang*, Xiang-Hui Yu*, Wei Kong. Doxorubicin Pretreatment Enhances FAPα/survivin Co-Targeting DNA Vaccine Anti-Tumor Activity Primarily Through Decreasing Peripheral MDSCs in the 4T1 Murine Breast Cancer Model.Oncoimmunology. 2020 Apr 16;9(1):1747350. 10. Fei Geng, Jie Guo, Qian-Qian Guo, Yu Xie, Ling Dong, Yi Zhou, Chen-Lu Liu, Bin Yu, Hui Wu, Jia-Xin Wu, Hai-Hong Zhang*, Wei Kong*, Xiang-Hui Yu*. A DNA vaccine expressing an optimized secreted FAPα induces enhanced anti-tumor activity by altering the tumor microenvironment in a murine model of breast cancer. Vaccine 2019,37(31):4382-4391. 11. Chenlu Liu, Zhenzhen Lu, Yu Xie, Qianqian Guo, Fei Geng, Bo Sun, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu, Wei Kong, Haihong Zhang*, Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect. Immunology letter. 2018 Jun 9; 200:33-42. 12. Chenlu Liu, Yu Xie, Bo Sun, Fei Geng, Fangfang Zhang, Qianqian Guo, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu, Wei Kong, Haihong Zhang*.MUC1- and survivin - based DNA vaccine combining immunoadjuvants CpG and interleukin 2 in bicistronic expression plasmid generates specific immune responses and anti-tumor effects in a murine colorectal carcinoma modelScand J Immunol. 2018 Feb; 87 (2):63-72. 13. Qiu Xia, Fei Geng, Fang-Fang Zhang, Chen-Lu Liu, Ping Xu, Zhen-Zhen Lu, Yu Xie, Hui Wu，Bo Sun, Wei Kong, Xiang-Hui Yu, Hai-Hong Zhang*. Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein α-based DNA vaccine in tumor-bearing mice with murine breast carcinoma.Immunopharmacol Immunotoxicol. 2017 Feb;39(1):37-44. 14. Qiu Xia, Fang-Fang Zhang, Fei Geng, Chen-Lu Liu, Yu-Qian Wang, Ping Xu, Zhen-Zhen Lu, Yu Xie, Hui Wu, Yan Chen, Yong Zhang, Wei Kong, Xiang-Hui Yu, Hai-Hong Zhang*, Improvement of anti-tumor immunity of fibroblast activation protein a based vaccines by combination with cyclophosphamide in a murine model of breast cancer.Cellular Immunology. 2016 Dec; 310:89-98. 15. Qiu Xia, Fei Geng, Fang-Fang Zhang, Chen-Lu Liu, Ping Xu, Zhen-Zhen Lu, Bin Yu, Hui Wu, Jia-Xin Wu, Hai-Hong Zhang*, Wei Kong, Xiang-Hui Yu.Enhancement of FAPα-targeted immunotherapy and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice. Vaccine. 2016 Aug 31; 34(38): 4526-35. 16. Haihong Zhang, Chenlu Liu, Qiu Xia, Zhenzhen Lu, Ping Xu, Fangfang Zhang, Fei Geng, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu*, and Wei Kong*，MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model. Vaccine. 2016 May 23; 34(24):2648-55. 17. Qiu Xia, Fang‑Fang Zhang, Fei Geng, Chen‑Lu Liu, Ping Xu, Zhen‑Zhen Lu, Bin Yu, Hui Wu, Jia‑Xin Wu, Hai‑Hong Zhang*, Wei Kong, Xiang‑Hui Yu. Anti‑tumor effects of DNA vaccine targeting human fibroblast activation protein α by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model.Cancer Immunology Immunotherapy. 2016 May; 65(5):613-24. doi: 10.1007/s00262-016-1827-4. 18. YuQian Wang, Chenlu Liu, Qiu Xia, Wang Peng, Bo Li, Zhenzhen Lu, Jiaxi Sun, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu, Wei Kong, HaiHong Zhang* and Xianling Cong*. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs. Oncol Rep.2014 Mar;31(3):1437-44. 19. Hui Wu#, Haihong Zhang#, Yue Hu, Qiu Xia, Chenlu Liu, Yingnan Li, Bin Yu, Tiejun Gu, Xizhen Zhang, Xianghui Yu,* and Wei Kong,*.Sphere Formation Assay is Not an Effective Method for Cancer Stem Cell Derivation and Characterization from the Caco-2 Colorectal Cell Line. Curr Stem Cell Res Ther. 2014 Mar; 9(2):82-8. 20. Hui Wu,† Haihong Zhang,† Peng Wang, Zhuo Mao, Li Feng, Yuqian Wang, Chenlu Liu, Qiu Xia, Bo Li, Heya Zhao, Yan Chen, Jiaxin Wu, Wei Kong,* Xianghui Yu*，Short-Form CDYLb but not long-form CDYLa functions cooperatively with histone methyltransferase G9a in hepatocellular carcinomas. Genes Chromosomes Cancer. 2013 Jul; 52(7):644-55. 21. Yu-Qian Wang1, Hai-Hong Zhang1, Chen-Lu Liu, Hui Wu, Peng Wang, Qiu Xia, Li-Xing Zhang, Bo Li, Jia-Xin Wu, Bin Yu, Tie-Jun Gu, Xiang-Hui Yu*, Wei Kong*. Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model. International Immunopharmacology.2013 Apr 25; 17(1):9-17. 22. Yu-Qian Wang&, Hai-Hong Zhang&, Chen-Lu Liu, Qiu Xia, Hui Wu, Xiang-Hui Yu*, Wei Kong*. Correlation between auto-antibodies to survivin and MUC1 VNTR in colorectal cancer. Asian Pacific Journal of Cancer Prevention. 2012, 13: 5557-62. 23. Haihong Zhang, Yuqian Wang, Chenlu Liu, Lixing Zhang, Qiu Xia, Yong Zhang, Jiaxin Wu, Chunlai Jiang, Yan Chen, Yongge Wu, Xiao Zha, Xianghui Yu* and Wei Kong*. DNA and Adenovirus Tumor Vaccine Expressing Truncated Survivin Generates Specific Immune Responses and Antitumor Effects in a Murine Melanoma Model. Cancer Immunology Immunotherapy. 2012，61:1857–1867 24. ZHANG Haihong, ZHANG Shuzi, YU Xianghui, KONG Wei*. Construction and Expression of Human Survivin and Preparation of Its Polyclonal Antibody. Chemical Research In Chinese Universities. 2008 24(6), 767-770.
专利 1. 以人源LIGHT截短型突变蛋白为基础的抗肿瘤的应用(申请号：202211381334.9)发明人：张海红；于湘晖；孔维；董玲；耿飞；郭杰
2. 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用(专利申请号：201911237825.4 ) 发明人：张海红；于湘晖；孔维；耿飞；郭杰。 3. 以序列优化的分泌形式的FAPα为基础的肿瘤DNA疫苗的应用(专利申请号：201910498855.4)，发明人：张海红；于湘晖；孔维；耿飞；郭杰 4. 以FAPα的CTL表位肽为基础的肽类疫苗和微基因疫苗的应用（专利号：ZL201711060548.5）, 发明人：张海红、于湘晖、孔维、张芳芳、刘晨露、徐平、耿飞、谢雨、郭倩倩、陆臻桢， 5. 以成纤维激活蛋白α为靶点的肿瘤DNA疫苗及病毒载体疫苗（专利号： ZL201610363126.4），发明人：张海红 于湘晖 孔维 夏秋 耿飞， 6. 以粘蛋白1和生存素为靶点的肿瘤DNA疫苗和病毒载体疫苗（专利号：ZL200910252427.x），发明人：孔维；张海红；于湘晖；于永慧 7. 以粘蛋白1和生存素为靶点的肿瘤基因工程疫苗（专利号：ZL201110086366.1），发明人：孔维 张海红 于湘晖 于永慧 王玉倩 张丽星 8. 以粘蛋白1和生存素为靶点的肿瘤DNA疫苗及病毒载体疫苗-分案（申请号:ZL201410189139.5），发明人：孔维；张海红；于湘晖；于永慧 9. 重组疫苗及其应用（申请号201711190257.8），发明人：孔维，张海红，于湘晖，陆臻桢，刘晨露，徐萍，耿飞，张芳芳，谢雨，郭倩倩 10. 国际专利名称：重组疫苗及其应用（申请号PCTCN2018116393，申请日：20181120 优先权日：2017.11.24），发明人：孔维，张海红，于湘晖，陆臻桢，刘晨露，徐萍，耿飞，张芳芳，谢雨，郭倩倩
|
